

# Daoud Al-Badriyeh

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1337146/daoud-al-badriyeh-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44  
papers

338  
citations

11  
h-index

16  
g-index

48  
ext. papers

425  
ext. citations

4.9  
avg, IF

3.49  
L-index

#	Paper	IF	Citations
44	Cost-Benefit Analysis of Genotype-Guided Interruption Days in Warfarin Pre-Procedural Management.. <i>Current Problems in Cardiology</i> , <b>2022</b> , 101128	17.1	
43	The economic impact of optimizing a COVID-19 management protocol in pre-existing cardiovascular disease patients.. <i>Current Problems in Cardiology</i> , <b>2022</b> , 101177	17.1	
42	A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.. <i>Current Problems in Cardiology</i> , <b>2022</b> , 101211	17.1	1
41	Intracoronary pharmacological therapy versus aspiration thrombectomy in STEMI (IPAT-STEMI): A systematic review and meta-analysis of randomized trials.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0263270	3.7	2
40	Clinical and Economic Evaluation of the Impact of Midazolam on Morphine Therapy for Pain Relief in Critically Ill Ventilated Infants with Respiratory Distress Syndrome. <i>Paediatric Drugs</i> , <b>2021</b> , 23, 143-157	4.2	0
39	First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis. <i>Current Problems in Cardiology</i> , <b>2021</b> , 100852	17.1	3
38	Use of ibuprofen for the closure of patent ductus arteriosus in preterm infants: a systematic review of meta-analyses. <i>Journal of Comparative Effectiveness Research</i> , <b>2021</b> , 10, 549-568	2.1	1
37	Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar. <i>International Journal of Cardiology</i> , <b>2021</b> , 331, 27-34	3.2	1
36	Periprocedural Anticoagulation Management of Patients receiving Warfarin in Qatar: A Prospective Cohort Study. <i>Current Problems in Cardiology</i> , <b>2021</b> , 46, 100816	17.1	1
35	Cost-effectiveness of Oral Versus Intravenous Ibuprofen Therapy in Preterm Infants With Patent Ductus Arteriosus in the Neonatal Intensive Care Setting: A Cohort-based Study. <i>Clinical Therapeutics</i> , <b>2021</b> , 43, 336-348.e7	3.5	1
34	Genetic and Non-Genetic Factors Impact on INR Normalization in Preprocedural Warfarin Management. <i>Pharmacogenomics and Personalized Medicine</i> , <b>2021</b> , 14, 1069-1080	2.1	
33	Cost-Effectiveness of Empagliflozin and Metformin Combination Versus Standard Care as First-Line Therapy in Patients With Type 2 Diabetes Mellitus. <i>Endocrine Practice</i> , <b>2021</b> ,	3.2	1
32	Bridging vs Non-Bridging with Warfarin Peri-Procedural Management: Cost and Cost-Effectiveness Analyses. <i>Current Problems in Cardiology</i> , <b>2021</b> , 46, 100839	17.1	0
31	Efficacy and Safety of Ibuprofen Plus Paracetamol in a Fixed-Dose Combination for Acute Postoperative Pain in Adults: Meta-Analysis and a Trial Sequential Analysis. <i>CNS Drugs</i> , <b>2021</b> , 35, 105-120	6.7	3
30	Surfactant therapy for meconium aspiration syndrome in neonates: a systematic overview of systematic reviews and recent clinical trials. <i>Journal of Comparative Effectiveness Research</i> , <b>2020</b> , 9, 527-536	2.1	3
29	Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses. <i>Paediatric Drugs</i> , <b>2020</b> , 22, 399-408	4.2	6
28	Vancomycin therapeutic drug monitoring service quality indices and clinical effectiveness outcomes: A retrospective cohort and clinical audit. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , <b>2020</b> , 3, 778-785	1.4	2

27	Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2020</b> , 25, 201-211	2.6	10
26	Cost-benefit analysis of clinical pharmacist intervention in preventing adverse drug events in the general chronic diseases outpatients. <i>Journal of Evaluation in Clinical Practice</i> , <b>2020</b> , 26, 115-124	2.5	10
25	Assessment of the attitude, awareness and practice of periprocedural warfarin management among health care professional in Qatar. A cross sectional survey. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 50, 957-968	5.1	3
24	Cost-effectiveness Evaluations Among the Direct Oral Anticoagulants for the Prevention and Treatment of Venous Thromboembolism: Systematic Review. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2019</b> , 25, 1076029619849103	3.3	6
23	Clinical and Pharmacokinetic Outcomes of Peak-Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring Approaches: A Pragmatic Randomized Controlled Trial. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>2019</b> , 44, 639-652	2.7	11
22	Clinical and Economic Analysis of Morphine Versus Fentanyl in Managing Ventilated Neonates With Respiratory Distress Syndrome in the Intensive Care Setting. <i>Clinical Therapeutics</i> , <b>2019</b> , 41, 714-727.e8	3.5	6
21	Prophylactic Sildenafil in Preterm Infants at Risk of Bronchopulmonary Dysplasia: A Pilot Randomized, Double-Blinded, Placebo-Controlled Trial. <i>Clinical Drug Investigation</i> , <b>2019</b> , 39, 1093-1107	3.2	8
20	Evaluations of Morphine and Fentanyl for Mechanically Ventilated Patients With Respiratory Disorders in Intensive Care: A Systematic Review of Methodological Trends and Reporting Quality. <i>Value in Health Regional Issues</i> , <b>2019</b> , 19, 7-25	1.6	1
19	Pharmacoeconomics Evaluations of Oral Anticancer Agents: Systematic Review of Characteristics, Methodological Trends, and Reporting Quality. <i>Value in Health Regional Issues</i> , <b>2018</b> , 16, 46-60	1.6	1
18	Cost-effectiveness research in cancer therapy: a systematic review of literature trends, methods and the influence of funding. <i>BMJ Open</i> , <b>2017</b> , 7, e012648	3	14
17	Open-Label Study of Absorption and Clearance of 1% Voriconazole Eye Drops. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 6896-6898	5.9	5
16	Multi-indication Pharmacotherapeutic Multicriteria Decision Analytic Model for the Comparative Formulary Inclusion of Proton Pump Inhibitors in Qatar. <i>Clinical Therapeutics</i> , <b>2016</b> , 38, 1158-73	3.5	9
15	Assessing the effectiveness of a pharmacist-delivered smoking cessation program in the State of Qatar: study protocol for a randomized controlled trial. <i>Trials</i> , <b>2015</b> , 16, 65	2.8	8
14	Implications of external price referencing of pharmaceuticals in Middle East countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2015</b> , 15, 993-8	2.2	24
13	Statin Selection in Qatar Based on Multi-indication Pharmacotherapeutic Multi-criteria Scoring Model, and Clinician Preference. <i>Clinical Therapeutics</i> , <b>2015</b> , 37, 2798-810	3.5	4
12	Pharmacoeconomic evaluation of voriconazole vs. liposomal amphotericin B in empiric treatment of invasive fungal infections in Turkey. <i>BMC Infectious Diseases</i> , <b>2013</b> , 13, 560	4	8
11	Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 1669-78	5.1	16
10	Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia. <i>Mycoses</i> , <b>2012</b> , 55, 244-56	5.2	5

9	Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis. <i>Clinical Ophthalmology</i> , <b>2010</b> , 4, 391-405	2.5	44
8	Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2010</b> , 65, 1052-61	5.1	25
7	Pharmacoeconomics of voriconazole in the management of invasive fungal infections. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2010</b> , 10, 623-36	2.2	5
6	Successful salvage treatment of <i>Scedosporium apiospermum</i> keratitis with topical voriconazole after failure of natamycin. <i>Annals of Pharmacotherapy</i> , <b>2009</b> , 43, 1139-42	2.9	11
5	Prospective open-label study of the administration of two-percent voriconazole eye drops. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 3153-5	5.9	10
4	Successful use of topical voriconazole 1% alone as first-line antifungal therapy against <i>Candida albicans</i> keratitis. <i>Annals of Pharmacotherapy</i> , <b>2009</b> , 43, 2103-7	2.9	11
3	Stability of extemporaneously prepared voriconazole ophthalmic solution. <i>American Journal of Health-System Pharmacy</i> , <b>2009</b> , 66, 1478-83	2.2	19
2	Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2009</b> , 63, 1276-85	5.1	19
1	Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2009</b> , 63, 197-208	5.1	20